Use of a botulinum toxin to improve gastric emptying and/or to treat GERD

• US 7,910,116 B2
• Filed: 08/24/2005
• Issued: 03/22/2011
• Est. Priority Date: 08/24/2005
• Status: Expired due to Fees

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Inventors: Aurora, Sheena K.
• Primary Examiner(s): Ford; Vanessa L.
• Application Number:
  US11/211,311
• Publication Number:
  US 20070048334A1
• Time in Patent Office: 2,036 Days
• Field of Search: 424/184.1, 424/234.1, 424/236.1, 424/247.1, 530/300
• US Class Current: 424/247.1
• CPC Class Codes: A61K 38/4893 Botulinum neurotoxin (3.4.24.69)

Abstract

Methods for treating gastric disorders, such as GERD and delayed gastric emptying, by intramuscular administration of a botulinum toxin to a head, neck and/or shoulder muscle of a patient with a gastric disorder.

Claims

1. A method for treating gastroesophageal reflux disease the method comprising the step of administering a therapeutically effective amount of a botulinum toxin to a head, neck and/or shoulder location of a patient with gastroesophageal reflux disease by intradermal or intramuscular injection, the botulinum toxin reducing a symptom of the gastroesophageal reflux disease, thereby treating the gastroesophageal reflux disease, wherein the therapeutically effective amount of a botulinum toxin is that amount which causes at least an alleviation of a symptom of the gastroesophageal reflux disease, as observed clinically, without a systemic toxicity resulting.

2. The method of claim 1, wherein the botulinum toxin is selected from the group consisting of botulinum toxins types A, B, C₁, D, E, F and G.

3. The method of claim 1, wherein the botulinum toxin is a botulinum toxin type A.

4. The method of claim 1, wherein the administration step is carried out by intramuscular administration of the botulinum toxin to a head, neck and/or shoulder muscle of the patient.

5. The method of claim 1, wherein the patient also has a headache.

6. The method of claim 1, wherein the patient also has a headache selected from the group consisting of a tension headache, migraine, cluster headache, sinus headache and cervogenic headache.

7. The method of claim 1, wherein the botulinum toxin is a botulinum toxin complex.

8. The method of claim 1, wherein the botulinum toxin is a pure botulinum toxin.

9. A method for treating GERD, the method comprising the step of intramuscular administration of a therapeutically effective amount of a botulinum toxin type A to a head, neck and/or shoulder muscle of a patient with GERD, the botulinum toxin reducing a symptom of GERD, thereby treating GERD;

wherein the therapeutically effective amount of a botulinum toxin is that amount which causes at least an alleviation of a symptom of GERD, as observed clinically, without a systemic toxicity resulting.

10. The method of claim 9, wherein the botulinum toxin administered is in an amount between about 1 unit and about 500 units.

11. The method of claim 9, wherein the botulinum toxin is administered to a muscle selected from the group consisting of the frontalis, glabellar, occipitalis, temporalis, masseter, trapezius, semispinalis and splenius capitis muscles.

12. A method for treating GERD, the method comprising the step of intramuscular administration therapeutically effective amount of a botulinum toxin type A to each of the frontalis, glabellar, occipitalis, temporalis, masseter;

trapezius, semispinalis and splenius capitis muscles of a patient with GERD, the botulinum toxin reducing a symptom of GERD, thereby treating GERD, wherein the therapeutically effective amount of a botulinum toxin type A is that amount which causes at least an alleviation of a symptom of GERD, as observed clinically, without a significant systemic toxicity resulting.